You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| REVENUES: | ||||
| Revenues | $ 41,090,137 | $ 20,680,550 | $ 104,098,237 | $ 54,559,758 |
| Cost of product revenue | 31,433,496 | 20,295,213 | 83,010,156 | 56,897,959 |
| Gross profit (loss) | 9,656,641 | 385,337 | 21,088,081 | (2,338,201) |
| OPERATING EXPENSES: | ||||
| Research and development | 1,041,947 | 770,557 | 2,539,444 | 2,917,072 |
| Plasma center operating expenses | 4,859,450 | 3,146,221 | 12,755,525 | 8,191,890 |
| Amortization of intangible assets | 178,838 | 178,838 | 536,514 | 536,514 |
| Selling, general and administrative | 12,893,139 | 10,726,797 | 38,563,136 | 31,198,880 |
| Total operating expenses | 18,973,374 | 14,822,413 | 54,394,619 | 42,844,356 |
| LOSS FROM OPERATIONS | (9,316,733) | (14,437,076) | (33,306,538) | (45,182,557) |
| OTHER INCOME (EXPENSE): | ||||
| Interest income | 7,236 | 4,256 | 42,573 | 32,241 |
| Interest expense | (5,580,366) | (3,298,680) | (13,542,419) | (9,741,110) |
| Loss on extinguishment of debt | 0 | 0 | (6,669,941) | 0 |
| Other expense | (9,641) | 18,546 | (195,942) | (106,772) |
| Other expense, net | (5,582,771) | (3,275,878) | (20,365,729) | (9,815,641) |
| NET LOSS | $ (14,899,504) | $ (17,712,954) | $ (53,672,267) | $ (54,998,198) |
| BASIC LOSS PER COMMON SHARE (in dollars per share) | $ (0.08) | $ (0.13) | $ (0.27) | $ (0.44) |
| DILUTED LOSS PER COMMON SHARE (in dollars per share) | $ (0.08) | $ (0.13) | $ (0.27) | $ (0.44) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||
| Basic (in shares) | 196,383,935 | 133,770,147 | 196,204,893 | 125,682,400 |
| Diluted (in shares) | 196,383,935 | 133,770,147 | 196,204,893 | 125,682,400 |
| Product Revenue [Member] | ||||
| REVENUES: | ||||
| Revenues | $ 41,054,429 | $ 20,644,842 | $ 103,991,112 | $ 54,452,633 |
| License Revenue [Member] | ||||
| REVENUES: | ||||
| Revenues | $ 35,708 | $ 35,708 | $ 107,125 | $ 107,125 |
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|